6月26日 - ** 药物开发商AltimmuneALT.O股价盘前下跌62%，至2.94美元
** 该公司称，在一项中期研究中，其试验性肥胖症药物培美度肽帮助一种脂肪肝患者缓解了病情，且肝脏瘢痕没有恶化
** 然而，该药物对代谢功能障碍相关性脂肪性肝炎（metabolic dysfunction-associated steatohepatitis(MASH) - ALT）患者肝脏瘢痕或纤维化的改善并无统计学意义。
** Citzensbank 分析师乔纳森-沃勒本（Jonathan Wolleben）说："虽然总体数据看起来不错，但在纤维化方面缺乏统计学意义将使投资者难以释怀"。
** 截至上次收盘，股价年累计上涨约 7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.